Patented therapeutic RNAi strategies for neurodegenerative diseases of the CNS

Antonio Orlacchio, Giorgio Bernardi, Aldo Orlacchio, Sabata Martino

Research output: Contribution to journalArticle

Abstract

Background: Owing to its biological properties, RNA interference (RNAi) holds the greatest promise as a therapeutic agent for the treatment of a wide range of diseases. The following review is based on the most recent discoveries of RNAi biological mechanisms, highlighting their efficacy, safety, in vivo delivery and use in future clinical trials. Objectives: This review highlights recent advances in RNAi research and focuses on RNAi therapeutic patents for neurodegenerative diseases of the CNS. Method: We used online database free patent resources to summarize RNAi discoveries with particular attention to those regarding the CNS application. We attempted to include the major contributions in the field, and the list of patents reviewed should be considered exhaustive. Conclusion: Patents cover a wide range of RNAi-related fields: molecular findings for understanding RNAi mechanisms, delivery systems and RNAi-based therapeutic applications for neurodegenerative diseases of the CNS.

Original languageEnglish
Pages (from-to)1161-1174
Number of pages14
JournalExpert Opinion on Therapeutic Patents
Volume18
Issue number10
DOIs
Publication statusPublished - Oct 2008

Fingerprint

RNA Interference
Neurodegenerative Diseases
Patents
Therapeutics
Clinical Trials
Databases
Safety
Research

Keywords

  • CNS
  • Neurodegenerative diseases
  • RNAi
  • RNAi delivery systems
  • RNAi therapeutics

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Patented therapeutic RNAi strategies for neurodegenerative diseases of the CNS. / Orlacchio, Antonio; Bernardi, Giorgio; Orlacchio, Aldo; Martino, Sabata.

In: Expert Opinion on Therapeutic Patents, Vol. 18, No. 10, 10.2008, p. 1161-1174.

Research output: Contribution to journalArticle

Orlacchio, Antonio ; Bernardi, Giorgio ; Orlacchio, Aldo ; Martino, Sabata. / Patented therapeutic RNAi strategies for neurodegenerative diseases of the CNS. In: Expert Opinion on Therapeutic Patents. 2008 ; Vol. 18, No. 10. pp. 1161-1174.
@article{3ddaabca616c4450b86f4c098acd62e4,
title = "Patented therapeutic RNAi strategies for neurodegenerative diseases of the CNS",
abstract = "Background: Owing to its biological properties, RNA interference (RNAi) holds the greatest promise as a therapeutic agent for the treatment of a wide range of diseases. The following review is based on the most recent discoveries of RNAi biological mechanisms, highlighting their efficacy, safety, in vivo delivery and use in future clinical trials. Objectives: This review highlights recent advances in RNAi research and focuses on RNAi therapeutic patents for neurodegenerative diseases of the CNS. Method: We used online database free patent resources to summarize RNAi discoveries with particular attention to those regarding the CNS application. We attempted to include the major contributions in the field, and the list of patents reviewed should be considered exhaustive. Conclusion: Patents cover a wide range of RNAi-related fields: molecular findings for understanding RNAi mechanisms, delivery systems and RNAi-based therapeutic applications for neurodegenerative diseases of the CNS.",
keywords = "CNS, Neurodegenerative diseases, RNAi, RNAi delivery systems, RNAi therapeutics",
author = "Antonio Orlacchio and Giorgio Bernardi and Aldo Orlacchio and Sabata Martino",
year = "2008",
month = "10",
doi = "10.1517/13543776.18.10.1161",
language = "English",
volume = "18",
pages = "1161--1174",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Patented therapeutic RNAi strategies for neurodegenerative diseases of the CNS

AU - Orlacchio, Antonio

AU - Bernardi, Giorgio

AU - Orlacchio, Aldo

AU - Martino, Sabata

PY - 2008/10

Y1 - 2008/10

N2 - Background: Owing to its biological properties, RNA interference (RNAi) holds the greatest promise as a therapeutic agent for the treatment of a wide range of diseases. The following review is based on the most recent discoveries of RNAi biological mechanisms, highlighting their efficacy, safety, in vivo delivery and use in future clinical trials. Objectives: This review highlights recent advances in RNAi research and focuses on RNAi therapeutic patents for neurodegenerative diseases of the CNS. Method: We used online database free patent resources to summarize RNAi discoveries with particular attention to those regarding the CNS application. We attempted to include the major contributions in the field, and the list of patents reviewed should be considered exhaustive. Conclusion: Patents cover a wide range of RNAi-related fields: molecular findings for understanding RNAi mechanisms, delivery systems and RNAi-based therapeutic applications for neurodegenerative diseases of the CNS.

AB - Background: Owing to its biological properties, RNA interference (RNAi) holds the greatest promise as a therapeutic agent for the treatment of a wide range of diseases. The following review is based on the most recent discoveries of RNAi biological mechanisms, highlighting their efficacy, safety, in vivo delivery and use in future clinical trials. Objectives: This review highlights recent advances in RNAi research and focuses on RNAi therapeutic patents for neurodegenerative diseases of the CNS. Method: We used online database free patent resources to summarize RNAi discoveries with particular attention to those regarding the CNS application. We attempted to include the major contributions in the field, and the list of patents reviewed should be considered exhaustive. Conclusion: Patents cover a wide range of RNAi-related fields: molecular findings for understanding RNAi mechanisms, delivery systems and RNAi-based therapeutic applications for neurodegenerative diseases of the CNS.

KW - CNS

KW - Neurodegenerative diseases

KW - RNAi

KW - RNAi delivery systems

KW - RNAi therapeutics

UR - http://www.scopus.com/inward/record.url?scp=56349091881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349091881&partnerID=8YFLogxK

U2 - 10.1517/13543776.18.10.1161

DO - 10.1517/13543776.18.10.1161

M3 - Article

AN - SCOPUS:56349091881

VL - 18

SP - 1161

EP - 1174

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 10

ER -